PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: MARKET SEGMENTATION BY PRODUCT • Market segmentation by product • Comparison by product • Small molecules - Market size and forecast 2018-2023 • Biologics - Market size and forecast 2018-2023 • Market opportunity by product PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 11: MARKET TRENDS PART 12: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 13: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • AbbVie Inc. • Amgen Inc. • Celgene Corp. • Eisai Co. Ltd. • F. Hoffmann-La Roche Ltd. • Johnson & Johnson Services Inc. • Mylan NV • Novartis AG • Pfizer Inc. • Takeda Pharmaceutical Co. Ltd. PART 14: APPENDIX • Research methodology • List of abbreviations • Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Product overview Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Product - Market share 2018-2023 (%) Exhibit 19: Comparison by product Exhibit 20: Small molecules - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Small molecules - Year-over-year growth 2019-2023 (%) Exhibit 22: Biologics - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Biologics - Year-over-year growth 2019-2023 (%) Exhibit 24: Market opportunity by product Exhibit 25: Customer landscape Exhibit 26: Market share by geography 2018-2023 (%) Exhibit 27: Geographic comparison Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 29: North America - Year-over-year growth 2019-2023 (%) Exhibit 30: Top 3 countries in North America Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 32: Europe - Year-over-year growth 2019-2023 (%) Exhibit 33: Top 3 countries in Europe Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 35: Asia - Year-over-year growth 2019-2023 (%) Exhibit 36: Top 3 countries in Asia Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 38: ROW - Year-over-year growth 2019-2023 (%) Exhibit 39: Top 3 countries in ROW Exhibit 40: Key leading countries Exhibit 41: Market opportunity Exhibit 42: Drug designations Exhibit 43: Side effects of small molecule-based drugs used for treatment of Behcet’s disease Exhibit 44: Impact of drivers and challenges Exhibit 45: Vendor landscape Exhibit 46: Landscape disruption Exhibit 47: Vendors covered Exhibit 48: Vendor classification Exhibit 49: Market positioning of vendors Exhibit 50: AbbVie Inc. - Vendor overview Exhibit 51: AbbVie Inc. - Business segments Exhibit 52: AbbVie Inc. - Organizational developments Exhibit 53: AbbVie Inc. - Geographic focus Exhibit 54: AbbVie Inc. - Key offerings Exhibit 55: AbbVie Inc. - Key customers Exhibit 56: Amgen Inc. - Vendor overview Exhibit 57: Amgen Inc. - Product segments Exhibit 58: Amgen Inc. - Organizational developments Exhibit 59: Amgen Inc. - Geographic focus Exhibit 60: Amgen Inc. - Key offerings Exhibit 61: Amgen Inc. - Key customers Exhibit 62: Celgene Corp. - Vendor overview Exhibit 63: Celgene Corp. - Business segments Exhibit 64: Celgene Corp. - Organizational developments Exhibit 65: Celgene Corp. - Geographic focus Exhibit 66: Celgene Corp. - Key offerings Exhibit 67: Celgene Corp. - Key customers Exhibit 68: Eisai Co. Ltd. - Vendor overview Exhibit 69: Eisai Co. Ltd. - Business segments Exhibit 70: Eisai Co. Ltd. - Organizational developments Exhibit 71: Eisai Co. Ltd. - Geographic focus Exhibit 72: Eisai Co. Ltd. - Segment focus Exhibit 73: Eisai Co. Ltd. - Key offerings Exhibit 74: Eisai Co. Ltd. - Key customers Exhibit 75: F. Hoffmann-La Roche Ltd. - Vendor overview Exhibit 76: F. Hoffmann-La Roche Ltd. - Business segments Exhibit 77: F. Hoffmann-La Roche Ltd. - Organizational developments Exhibit 78: F. Hoffmann-La Roche Ltd. - Geographic focus Exhibit 79: F. Hoffmann-La Roche Ltd. - Segment focus Exhibit 80: F. Hoffmann-La Roche Ltd. - Key offerings Exhibit 81: F. Hoffmann-La Roche Ltd. - Key customers Exhibit 82: Johnson & Johnson Services, Inc. - Vendor overview Exhibit 83: Johnson & Johnson Services, Inc. - Business segments Exhibit 84: Johnson & Johnson Services, Inc. - Organizational developments Exhibit 85: Johnson & Johnson Services, Inc. - Geographic focus Exhibit 86: Johnson & Johnson Services, Inc. - Segment focus Exhibit 87: Johnson & Johnson Services, Inc. - Key offerings Exhibit 88: Johnson & Johnson Services, Inc. - Key customers Exhibit 89: Mylan NV - Vendor overview Exhibit 90: Mylan NV - Product segments Exhibit 91: Mylan NV - Organizational developments Exhibit 92: Mylan NV - Geographic focus Exhibit 93: Mylan NV - Segment focus Exhibit 94: Mylan NV - Key offerings Exhibit 95: Mylan NV - Key customers Exhibit 96: Novartis AG - Vendor overview Exhibit 97: Novartis AG - Business segments Exhibit 98: Novartis AG - Organizational developments Exhibit 99: Novartis AG - Geographic focus Exhibit 100: Novartis AG - Segment focus Exhibit 101: Novartis AG - Key offerings Exhibit 102: Novartis AG - Key customers Exhibit 103: Pfizer Inc. - Vendor overview Exhibit 104: Pfizer Inc. - Business segments Exhibit 105: Pfizer Inc. - Organizational developments Exhibit 106: Pfizer Inc. - Geographic focus Exhibit 107: Pfizer Inc. - Segment focus Exhibit 108: Pfizer Inc. - Key offerings Exhibit 109: Pfizer Inc. - Key customers Exhibit 110: Takeda Pharmaceutical Co. Ltd. - Vendor overview Exhibit 111: Takeda Pharmaceutical Co. Ltd. - Business segments Exhibit 112: Takeda Pharmaceutical Co. Ltd. - Organizational developments Exhibit 113: Takeda Pharmaceutical Co. Ltd. - Geographic focus Exhibit 114: Takeda Pharmaceutical Co. Ltd. - Key offerings Exhibit 115: Takeda Pharmaceutical Co. Ltd. - Key customers Exhibit 116: Validation techniques employed for market sizing Exhibit 117: Definition of market positioning of vendors

AbbVie Inc., Amgen Inc., Celgene Corp., Eisai Co. Ltd., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Mylan NV, Novartis AG, Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.